Evaluating the MyTatva App in Non Alcoholic Fatty Liver Disease Management
- Conditions
- Health Condition 1: K760- Fatty (change of) liver, not elsewhere classifiedHealth Condition 2: E889- Metabolic disorder, unspecified
- Registration Number
- CTRI/2024/07/070859
- Lead Sponsor
- Digicare Health Solutions Private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patients with confirmed diagnosis of NAFLD
Patients with Liver Stiffness Measure (LSM) Values ranges between 7 to 12 kPa measured via FibroScan
Patients with access to a smartphone with internet access/data plan
Patients or caregivers who understands and speaks English sufficiently to be able to use the MyTatva Patient application
Patient is willing to comply with all study procedures and available for the duration of study
Patients who have active or recent participation in lifestyle intervention program including a weight loss program less than 90 days before enrolment
Patients who are on active weight loss supplement use
Patients with LSM values above 12 kPa measured via FibroScan
Patients who are unable or not willing to provide informed consent
Patients with other chronic liver diseases
Patients who have secondary causes of hepatic steatosis,
including significant alcohol consumption for men more than 30gram per day and women more than 20gram day
Patients who have severe medical comorbidities or psychiatric illness can be excluded at the discretion of the study PI
Concurrent enrollment in any other interventional clinical trial at the start of study
Enrollment in any other interventional clinical trial 3 months prior to the start of study
Presumed or confirmed COVID-19 diagnosis within 30 days prior to study enrollment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method